PubMed Health⌕ Search

Biomedical subjects

H Trobisch

Publications and source records attributed to H Trobisch.

At least 37 records · Page 2Linked to original sources
PubMed1980

[Post-transfusional hepatitis B: a solvable problem? (author's transl)].

Forty-four patients with haemophilia A or von Willebrand-Jürgens syndrome were followed for three years. They received about 28 000 cryoprecipitate produced in the author's laboratories, without a single case of hepatitis B. There were seven among these patients who had no antibodies against surface antigen: they had received a total of 2533 cryoprecipitate. There were no seroconversion or transaminase changes in comparison with values before cryoprecipitates.

Aged↗
PubMed1980

[Diagnosis of the Paget-von Schroetter syndrome and monitoring of the therapeutic results (author's transl)].

Streptokinase or Urokinase can lead to complete healing in Paget-von Schroetter Syndrome. This tyne of lysis therapy should be instituted immediately or after the fourteenth postthrombotic day. The diagnosis should be verified by armphlebography. The therapeutic results must be controlled by phlebography in order to point out the need for continued therapy in case of thrombotic residual.

Axillary Vein↗
PubMed1979

[Blood coagulation disorder in islet cell adenoma].

Coagulation physiologic tests were carried out and plasminogen activity and concentration were measured in the case of 6 patients (5 islet cell adenomas and 1 islet cell carcinoma). Except a reduced plasminogen activity in the postoperative phase no other unequivocally pathologic data were found. This phenomenon can probably by attributed to the enhanced plasmin inhibitors of the human plasma. The problem of so-called hypercoagulaemia of these patients can be clarified only after the investigation of the half-lives of the various coagulation factors.

Adenoma↗
PubMed1978

[Concentration of specific antibodies in commercially avaialable immunoglobulins (author's transl)].

Not significant differences in the composition or concentration of specific antibodies against microbial antigens could be measured in five commercially available human immunoglobulin preparations for intravenous use. Prediction of prophylactic or therapeutic efficiency of such preparations according to their antibody content seems to be only partially possible. Human immunoglobulins for intravenous use should be free from irregular antibodies against erythrocyte antigens of the Rh-systems, as found in one of the specimens tested.

Antibodies↗
PubMed1976

[New aspects in the treatment of pneumonitis (author's transl)].

Two groups of patients suffering from pneumonitis received different treatments and were compared retrospectively. The first group (38 patients) was treated with heparin and aprotinin. The overall mortality was 50 percent; of the patients who were artifically ventilated 64 percent died. The second group (60 patients) was treated with heparin, fresh-frozen plasma, nicotinic acid, methylprednisolone, and alpha-receptor blocking agents. In this group the overall mortality was 26.5 percent and the mortality among the patients who were artificially ventilated was 33 percent. These results lead the authors to feel that the treatment of pneumonitis with aprotinin is no longer indicated.

Adolescent↗
PubMed1976

[Longtime therapy of congenital factor XIII deficiency using factor XIII concentrate].

Factor XIII was determined by enzymatic and immunochemical methods in 3 patients with congenital factor XIII deficiency. Factor XIII activity measured by trans-glutaminase assay was below 1% of normal value in each of these cases. Immunelectrophoresis determination revealed the absence of the functionally active subunit A, whereas subunit S was only slightly diminished (30 to 50% of the normal value). Substitution with factor XIII concentrate caused a parallel increase of factor XIII activity and subunit A concentration. No uptake of factor XIII activity or of subunit. A by platelets could be demonstrated. Despite discontinuous substitution over a period of six years no antibody against factor XIII activity could be demonstrated in one patient with congenital factor XIII deficiency.

Antibodies↗